TWiV 998: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses the White House COVID adviser calling on doctors to combat a vacuum of medical information, adeno-associated virus type 2 in US children with acute severe hepatitis, genomic investigations of unexplained acute hepatitis in children, surveillance of SARS-CoV-2 at the Huanan seafood market, vaccine effectiveness against hospitalization among adolescent and pediatric SARS-CoV-2 cases between May 2021 and January 2022 in Canada, effectiveness of BNT162b2 after extending the primary series dosing interval in children and adolescents aged 5–17, prevalence and characteristics associated with post–COVID-19 condition among non-hospitalized adolescents and young adults, within-host genetic diversity of SARS-CoV-2 lineages in unvaccinated and vaccinated individuals, live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters, Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2, COVID-19 convalescent plasma utilization in the United States, FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19, anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO), anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19, triple combination therapy with two antivirals and monoclonal antibodies for persistent or relapsed SARS-CoV-2 infection in immunocompromised patients, and the breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of long COVID symptoms.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- White House COVID adviser calls on doctors to combat medical information (STAT)
- Adeno-associated virus type 2 in US children with acute severe hepatitis (Nature)
- Genomic investigations of unexplained acute hepatitis in children (Nature)
- Surveillance of SARS-CoV-2 at the Huanan Seafood Market (ChinaXiv)
- Vaccine effectiveness against hospitalization among pediatric SARS-CoV-2 cases (PLOS)
- Effectiveness of BNT162b2 after extending the series dosing interval in children (Nature)
- Prevalence and characteristics associated with post–COVID-19 condition (JAMA)
- Within-host genetic diversity of SARS-CoV-2 lineages in unvaccinated and vaccinated individuals (Nature)
- Replication-competent-attenuated vaccine sCPD9 elicits immunity to SARS-CoV-2 variants (Nature)
- Fc-γR antibody functions needed for SARS-CoV-2 variant protection via vaccination (Nature)
- COVID-19 convalescent plasma utilization in the United States (CID)
- FDA authorizes Gohibic injection for the treatment of COVID-19 (FDA)
- IFX-1 antibody vs. supportive care for severe COVID-19 patients (Lancet)
- Vilobelimab therapy for COVID-19 critically ill patients on mechanical ventilation (Lancet)
- Triple combo therapy for relapsed SARS-CoV-2 in immunocompromised patients with antivirals and antibodies (CID)
- Neutralizing antibody response breadth to SARS-CoV-2 tied to Long COVID presence (medRxiv)
- Neurological Long COVID pathogenesis and potential therapies (Journal Cells)
- Contribute to our ASTMH fundraiser at PWB
- Dr. Griffin's treatment guide (pdf)
- Letters read on TWiV 998
- Don't crush Paxlovid (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
Available Results
Generated results are saved to your library for reuse and search.
Choose Template
Pick the result you want. You can review provider and model before generating.
A concise first-pass summary for understanding the episode quickly.
A comprehensive, source-grounded extraction of the reusable knowledge in an episode.
Technologies, AI models, technical methods, capabilities, limitations, and adoption implications.
Repeatable methods, frameworks, mental models, processes, and systems.
A dedicated analysis of warnings, limitations, trade-offs, weak evidence, and uncertainty.
A dedicated inventory of concrete resources named in the episode.
A concise first-pass summary for understanding the episode quickly.
A detailed readable summary organized by chapter or topic.
A navigable map of subjects, topic flow, and suggested chapters.
A comprehensive, source-grounded extraction of the reusable knowledge in an episode.
Reusable atomic knowledge units extracted from the episode.
A comprehensive extraction focused on health practices, protocols, claims, and safety caveats.
A comprehensive extraction focused on opportunities, strategy, markets, and company building.
Explicit actions, next steps, habits, recommendations, and things to avoid.
A dedicated inventory of concrete resources named in the episode.
A dedicated analysis of warnings, limitations, trade-offs, weak evidence, and uncertainty.
A concise first-pass summary for understanding the episode quickly.
A detailed readable summary organized by chapter or topic.
A navigable map of subjects, topic flow, and suggested chapters.
A comprehensive, source-grounded extraction of the reusable knowledge in an episode.
Reusable atomic knowledge units extracted from the episode.
A comprehensive extraction focused on health practices, protocols, claims, and safety caveats.
A comprehensive extraction focused on opportunities, strategy, markets, and company building.
Scientific findings, mechanisms, studies, hypotheses, and the limits of the evidence discussed.
Technologies, AI models, technical methods, capabilities, limitations, and adoption implications.
Investment theses, assets, catalysts, valuation reasoning, time horizons, and risks.
Chronologies, actors, causes, consequences, turning points, and competing historical interpretations.
Policies, proposals, stakeholders, arguments, implementation constraints, and predicted effects.
Career paths, skills, hiring signals, workplace decisions, transitions, and limitations of the advice.
Behavioral mechanisms, biases, motivation, habits, emotions, interventions, and evidence limitations.
Economic mechanisms, incentives, indicators, market structure, forecasts, and uncertainty.
Leadership principles, team systems, organizational design, culture, feedback, and failure modes.
Audience, positioning, messaging, acquisition, retention, experiments, metrics, and failed approaches.
Teaching methods, learning strategies, practice, feedback, assessment, and effectiveness evidence.
Theses, premises, arguments, objections, values, thought experiments, and unresolved questions.
Communication patterns, conflict, boundaries, expectations, repair methods, and contextual limitations.
Books, papers, authors, courses, and other learning resources mentioned in the episode.
Repeatable methods, frameworks, mental models, processes, and systems.
Explicit actions, next steps, habits, recommendations, and things to avoid.
Memorable statements and important claims with attribution and source context.
A dedicated inventory of concrete resources named in the episode.
A dedicated analysis of warnings, limitations, trade-offs, weak evidence, and uncertainty.